What are the diagnostic criteria for chronic myeloid leukemia and the staging criteria (chronic phase, accelerated phase, blast crisis) according to the older WHO definitions and the newer WHO/ELN updates?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

CML Diagnostic and Staging Criteria: Old vs. New

The 2025 ELN recommendations now align with the 2022 WHO classification, which fundamentally restructures CML as a biphasic disease (chronic phase and blast phase only), eliminating the traditional accelerated phase category and lowering the blast threshold for blast phase from ≥30% to ≥20%. 1

Diagnostic Criteria (Unchanged Core Elements)

The hallmark diagnostic requirement remains detection of the BCR::ABL1 fusion gene created by t(9;22) translocation (Philadelphia chromosome). At diagnosis, perform:

  • Bone marrow morphology and conventional chromosome banding analysis (CBA)
  • RT-PCR on peripheral blood or bone marrow to identify BCR::ABL1 transcript type
  • These tests detect variant translocations, cryptic rearrangements, and additional chromosomal abnormalities (ACA) 1

Critical pitfall: Some commercial RT-PCR kits don't recognize rare transcripts (like e1a2/p190). If you get discrepant results (negative RT-PCR with positive cytogenetics), investigate further 1, 2

Old Staging System (Pre-2022 WHO)

The traditional triphasic classification used in clinical trials and 2020 ELN recommendations:

Chronic Phase (CP)

  • <10% blasts in blood or marrow
  • <20% basophils in blood
  • Platelets >100 × 10⁹/L
  • No extramedullary disease

Accelerated Phase (AP) - MD Anderson Criteria

  • 10-19% blasts in blood or marrow
  • ≥20% basophils in blood
  • Platelets <100 × 10⁹/L unrelated to therapy
  • Clonal evolution (ACA in Ph+ cells)

Blast Phase (BP)

  • ≥30% blasts in blood or marrow
  • Extramedullary blast proliferation
  • Large clusters of blasts in bone marrow biopsy

3, 1, 4

New Staging System (2022 WHO/2025 ELN)

The accelerated phase has been eliminated. CML is now classified as:

Chronic Phase

  • <20% blasts in blood or marrow
  • Patients may have high-risk features (see below) but remain classified as CP

Blast Phase

  • ≥20% blasts in blood or marrow (lowered from ≥30%)
  • Extramedullary blast proliferation
  • Large clusters of blasts in bone marrow biopsy

1

High-Risk Features in Chronic Phase

The new classification recognizes patients can present with concerning features without reclassifying them as advanced phase:

  • Elevated blast percentage (10-19%)
  • Thrombocytopenia (<100 × 10⁹/L)
  • Basophilia (≥20%)
  • High-risk ACA (major route: +8, +Ph, i(17q), +19, +17, +21; minor route: -7/7q-, 11q23, 3q26.2)
  • Complex karyotypes

These features warrant closer monitoring and may influence treatment intensity but don't change phase classification 1

Rationale for the Change

The 2022 WHO revision was driven by several key observations:

  1. Genomic studies show CML is biologically biphasic: Genetic changes characteristic of blast phase are present in what was called "accelerated phase" but absent in chronic phase, suggesting AP represents early blast transformation 1

  2. Patients with 20-29% blasts behave more like those with ≥30% blasts than those with 10-19% blasts, supporting the lower threshold 1

  3. Alignment with AML criteria: Since AML diagnosis changed from ≥30% to ≥20% blasts, CML blast phase needed similar alignment 1

  4. Clinical practice reality: Most patients meeting old AP criteria at diagnosis respond to TKI therapy similarly to CP patients, making the distinction clinically less meaningful 1, 5

Practical Implications

For newly diagnosed patients: Approximately 6% previously classified as AP will now be classified as CP under 2022 WHO criteria 6. These patients typically receive standard TKI therapy with closer monitoring.

For treatment decisions: The blast percentage between 20-30% identifies patients who may benefit from more aggressive approaches including allogeneic stem cell transplantation when feasible 1

For emerging ACA during treatment: Additional chromosomal abnormalities appearing in Ph+ cells during therapy remain a warning sign of disease progression risk, regardless of classification system 1

Additional Diagnostic Considerations

  • BCR::ABL1 mutation testing at diagnosis is NOT recommended in chronic phase (mutations are rare) 1
  • Next-generation sequencing (NGS) IS recommended for patients presenting in or progressing to blast phase 1
  • Somatic mutations in non-BCR::ABL1 genes occur in 20-30% of patients but have unclear therapeutic implications in chronic phase; testing remains a research tool 1

The controversy continues, as some experts argue the long-standing triphasic system remains clinically useful 1. However, the 2025 ELN recommendations have adopted the 2022 WHO biphasic classification as the new standard 1.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.